PAVmed Inc (PAVM)

Currency in USD
9.570
+0.220(+2.35%)
Closed·
9.470-0.100(-1.04%)
·
PAVM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.4009.780
52 wk Range
6.00028.440
Key Statistics
Prev. Close
9.35
Open
8.7
Day's Range
8.4-9.78
52 wk Range
6-28.44
Volume
290.63K
Average Volume (3m)
975.53K
1-Year Change
-50.8096%
Book Value / Share
11.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PAVM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
285.000
Upside
+2,878.06%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

PAVmed Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

PAVmed Inc Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York

PAVmed Inc Earnings Call Summary for Q3/2025

  • PAVmed reported a Q3 2025 GAAP net loss of $6 million and non-GAAP loss of $446,000, causing a 4.65% stock decline in premarket trading to $0.369
  • The company launched its Veris commercial phase with Ohio State University and restructured 80% of outstanding debt into Series C preferred equity
  • PAVmed maintained a quarterly cash burn rate of $900,000 with average non-GAAP operating expenses of $4.4 million, while securing $4.9 million in Veris financing
  • CEO Dr. Lishan Aklog emphasized PAVmed's innovation focus as the company prepares for FDA submission of an implantable physiologic monitor in 2026
  • Future revenue forecasts project gradual growth to $0.49 million by FY2026, with strategic focus on expanding digital health technologies and Medicare coverage for EsoGuard
Last Updated: 2025-11-13, 09:40 a/m
Read Full Transcript

Compare PAVM to Peers and Sector

Metrics to compare
PAVM
Peers
Sector
Relationship
P/E Ratio
−14.8x−9.7x−0.6x
PEG Ratio
0.10−0.150.00
Price/Book
1.0x8.8x2.6x
Price / LTM Sales
304.0x7.4x3.3x
Upside (Analyst Target)
-41.4%45.0%
Fair Value Upside
Unlock−3.7%6.5%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 285.000
(+2,878.06% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Ascendiant Capital
Buy17.00+77.64%20.00MaintainDec 10, 2025
Cantor Fitzgerald
Hold4.00-58.20%4.00MaintainMar 10, 2025

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-0.29 / --
Revenue / Forecast
5.00K / 2.30M
EPS Revisions
Last 90 days

PAVM Income Statement

People Also Watch

1.160
IVF
-6.45%
4.35
SPHL
+2.59%
1.270
VERO
-9.29%
1.150
XAIR
0.00%
2.7600
SER
+1.47%

FAQ

What Is the PAVmed (PAVM) Stock Price Today?

The PAVmed stock price today is 9.570

What Stock Exchange Does PAVmed Trade On?

PAVmed is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for PAVmed?

The stock symbol for PAVmed is "PAVM."

What Is the PAVmed Market Cap?

As of today, PAVmed market cap is 8.68M.

What Is PAVmed's Earnings Per Share (TTM)?

The PAVmed EPS (TTM) is -6.65.

From a Technical Analysis Perspective, Is PAVM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has PAVmed Stock Split?

PAVmed has split 2 times.

How Many Employees Does PAVmed Have?

PAVmed has 39 employees.

What is the current trading status of PAVmed (PAVM)?

As of Feb 04, 2026, PAVmed (PAVM) is trading at a price of 9.570, with a previous close of 9.350. The stock has fluctuated within a day range of 8.400 to 9.780, while its 52-week range spans from 6.000 to 28.440.

What Is PAVmed (PAVM) Price Target According to Analysts?

The average 12-month price target for PAVmed is USD285.000, with a high estimate of USD510.00051 and a low estimate of USD60.00006. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,878.06% Upside potential.

What Is the PAVM Premarket Price?

PAVM's last pre-market stock price is 9.126. The pre-market share volume is 162,040.000, and the stock has decreased by -0.224, or -2.400%.

What Is the PAVM After Hours Price?

PAVM's last after hours stock price is 9.470, the stock has decreased by -0.100, or -1.040%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.